Falsely labelled semaglutide pens identified

No evidence of supply to patients

Pre-filled pens falsely labelled as the diabetes medicine Ozempic (semaglutide, 1 mg, solution for injection) have been identified at two UK wholesalers.

All affected pens have been recalled and accounted for, and none of the pens have been supplied to UK patients.

The falsely labelled products, under the brand name Ozempic, were brought in from legitimate suppliers in Austria and Germany, the MHRA has confirmed.

While the falsified pens appeared to have authentic German packaging, there are substantial differences compared with genuine pens. The German medicines agency, the Federal Institute for Drugs and Medical Devices (BfArM), has published photos of the genuine and falsified products.

There is no evidence that any of the falsified pens have been dispensed to patients from legitimate pharmacies or healthcare professionals in the UK and there are no reports of harm to patients in relation to these pens.

MHRA alert